MX2019002393A - Aminopirimidinas como inhibidores de alk. - Google Patents

Aminopirimidinas como inhibidores de alk.

Info

Publication number
MX2019002393A
MX2019002393A MX2019002393A MX2019002393A MX2019002393A MX 2019002393 A MX2019002393 A MX 2019002393A MX 2019002393 A MX2019002393 A MX 2019002393A MX 2019002393 A MX2019002393 A MX 2019002393A MX 2019002393 A MX2019002393 A MX 2019002393A
Authority
MX
Mexico
Prior art keywords
aminopyrimidines
alk inhibitors
formula
present disclosure
provides compounds
Prior art date
Application number
MX2019002393A
Other languages
English (en)
Inventor
Chen Jianyong
Wang Shaomeng
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2019002393A publication Critical patent/MX2019002393A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación proporciona compuestos representados por la Fórmula I: (ver Fórmula) y sus sales, hidratos y solvatos aceptables desde el punto de vista farmacéutico, en donde R1a, R1b, R2a, R2b, R3, R4, R5, R6 y R7 son como se definen en la memoria descriptiva. La presente divulgación también proporciona compuestos de Fórmula I para uso en el tratamiento de una afección o trastorno que responde a la inhibición de ALK tal como el cáncer.
MX2019002393A 2016-08-29 2017-08-28 Aminopirimidinas como inhibidores de alk. MX2019002393A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Publications (1)

Publication Number Publication Date
MX2019002393A true MX2019002393A (es) 2019-07-08

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002393A MX2019002393A (es) 2016-08-29 2017-08-28 Aminopirimidinas como inhibidores de alk.
MX2022000376A MX2022000376A (es) 2016-08-29 2019-02-27 Aminopirimidinas como inhibidores de alk.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000376A MX2022000376A (es) 2016-08-29 2019-02-27 Aminopirimidinas como inhibidores de alk.

Country Status (13)

Country Link
US (2) US10709705B2 (es)
EP (2) EP3504203B1 (es)
JP (2) JP7094566B2 (es)
KR (1) KR102530871B1 (es)
CN (2) CN115043821A (es)
AU (2) AU2017319135B2 (es)
BR (1) BR112019003897A2 (es)
CA (1) CA3033223A1 (es)
IL (1) IL264638B (es)
MX (2) MX2019002393A (es)
NZ (1) NZ751713A (es)
SG (2) SG10201914030UA (es)
WO (1) WO2018044767A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3758705A4 (en) * 2018-07-31 2021-08-04 Ascentage Pharma (Suzhou) Co., Ltd. CANCER TREATMENT METHOD USING A COMBINATION OF FAK / ALK / ROS1 INHIBITOR AND EGFR INHIBITOR
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
WO2020259553A1 (en) * 2019-06-25 2020-12-30 Ascentage Pharma (Suzhou) Co., Ltd. Combination of fak inhibitor and btk inhibitor for treating a disease
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022063220A1 (en) * 2020-09-25 2022-03-31 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
WO2022222932A1 (en) * 2021-04-19 2022-10-27 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical combination and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4607879B2 (ja) 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
AU2004272288B2 (en) * 2003-09-18 2008-11-13 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
ME02125B (me) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
UA100846C2 (uk) 2006-12-08 2013-02-11 Айерем Елелсі Сполуки та композиція як інгібітори протеїнкінази
MX2010010968A (es) 2008-04-07 2010-10-26 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX2013004086A (es) 2010-10-14 2013-07-05 Ariad Pharma Inc Metodos para inhibir proliferacion celular en cancers accionados por egfr.
US8703787B2 (en) * 2011-02-02 2014-04-22 Irm Llc Methods of using ALK inhibitors
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Also Published As

Publication number Publication date
BR112019003897A2 (pt) 2019-05-21
EP3504203B1 (en) 2022-09-28
JP2022120151A (ja) 2022-08-17
US20200330464A1 (en) 2020-10-22
EP4001273A2 (en) 2022-05-25
CN115043821A (zh) 2022-09-13
JP2019528307A (ja) 2019-10-10
KR20190039760A (ko) 2019-04-15
AU2017319135A1 (en) 2019-04-04
CN109715620B (zh) 2022-05-06
CN109715620A (zh) 2019-05-03
EP4001273A3 (en) 2022-08-24
KR102530871B1 (ko) 2023-05-09
US20190175595A1 (en) 2019-06-13
SG10201914030UA (en) 2020-03-30
CA3033223A1 (en) 2018-03-08
NZ751713A (en) 2022-07-01
US10709705B2 (en) 2020-07-14
SG11201901251SA (en) 2019-03-28
AU2021203098B2 (en) 2023-05-25
WO2018044767A2 (en) 2018-03-08
EP3504203A2 (en) 2019-07-03
AU2017319135B2 (en) 2021-03-18
JP7094566B2 (ja) 2022-07-04
AU2021203098A1 (en) 2021-06-10
MX2022000376A (es) 2022-02-10
IL264638B (en) 2021-08-31
WO2018044767A3 (en) 2018-04-12
US11110090B2 (en) 2021-09-07

Similar Documents

Publication Publication Date Title
MX2022000376A (es) Aminopirimidinas como inhibidores de alk.
MX2018013433A (es) Piperidinas como inhibidores de menina.
MX2018012174A (es) Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2).
MX2019011412A (es) Piperidinas como inhibidores de menina covalentes.
SA519401020B1 (ar) مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2
MX2023006257A (es) Inhibidores de smyd.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2018012379A (es) Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
MX2016011992A (es) Derivados de piperidina-diona.
TW201613865A (en) Heteroaryls and uses thereof
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
MA40170A (fr) Dérivés hétérocycliques de morphinan et leur utilisation
MX2017002986A (es) Compuestos de piperidina sustituidos.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2018004664A (es) Antagonistas de ep4.
MX2021004659A (es) Derivados de aminopirimidina/pirazina como inhibidores de ctps1.
PH12020551580A1 (en) Piperidine compounds as covalent menin inhibitor-0s
PH12021550374A1 (en) Small molecule menin inhibitors
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2021015514A (es) Compuesto heterociclico.